The U.S. Government is seeking information from industry partners to develop next-generation host-based diagnostic tests for chemical, biological, radiological, and nuclear (CBRN) threats, focusing on diagnosing infection through host biomarkers rather than direct pathogen detection. The goal is to create diagnostics that predict clinical outcomes, guide therapeutic selection, and monitor recovery for warfighters, with a preference for mature candidates at Technology Readiness Level (TRL) 4 or higher. The ideal product profile includes a small, rugged device with an assay time under 70 minutes, clinical sensitivity and specificity above 90%, and use of minimally invasive sample types like peripheral blood. Respondents must submit a white paper (max 3 pages) and a one-page Quad Chart detailing technical approach, regulatory status, manufacturing capabilities, and a Rough Order of Magnitude cost. Performance of services is not specified, but manufacturing facility location should be stated in responses.